Please assess the completion status of the following clinical trial:

Trial Title: A Rollover Protocol for Subjects Previously Treated With AGS-003

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Subjects are receiving ongoing treatment with AGS-003 in protocol AGS- 003-004 or AGS-003-006.~* Measurable disease that can be monitored per RECIST throughout the course of study participation.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Adequate hematologic function, as defined by the following criteria:~  1. White blood cell (WBC) ≥ 4000/µL (≥ 4.0 x 103/µL)~ 2. Absolute neutrophil count (ANC) ≥ 1500/µL (≥ 1.5 x 103/µL)~ 3. Platelets ≥ 100,000/µL (≥ 100 x 103/µL)~ 4. Hemoglobin (Hgb) ≥ 9.0 g/dL~* Adequate renal and hepatic function, as defined by the following criteria:~  1. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or, if serum creatinine \> 1.5 x ULN, estimated glomerular filtration rate (eGFR) ≥ 30 mL/min~ 2. Total serum bilirubin ≤ 1.5 x ULN~ 3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy~* Adequate coagulation function as defined by the following criteria:~  1. Prothrombin time (PT) ≤ 1.5 x ULN~ 2. Activated partial thromboplastin time (PTT) \< 1.5 x ULN~ 3. Corrected calcium ≤ 11.5 mg/dL~* Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug~* Able to abstain from taking prohibited drugs, either prescription or non- prescription, during the treatment phase of the study~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures~* Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment~* No brain metastases detected by magnetic resonance imaging (MRI).~Exclusion Criteria:~* Any serious medical condition considered by the investigator to constitute an unwarranted high risk for investigational treatment~* History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease on screening computed tomography (CT) scan or MRI~* Pregnancy or breastfeeding~* Active autoimmune disease or condition requiring chronic immunosuppressive therapy~NOTE: Abnormal laboratory values for autoimmunity markers in the absence of other signs/symptoms of autoimmune disease are not exclusionary.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AGS-003 in combination with sunitinib (Type: EXPERIMENTAL): Subjects will undergo Induction (AGS-003 every 3 weeks until 5 doses are administered) followed by Booster (AGS-003 at 3 month intervals). Subjects that will begin sunitinib therapy will be on this arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).